Division of Molecular Oncology and IIT Network Research Unit of Molecular Neuroscience, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy.
Med Res Rev. 2012 Sep;32(5):1078-91. doi: 10.1002/med.20238. Epub 2011 Feb 1.
Delivery and penetration of chemotherapeutic drugs into tumors are limited by a number of factors related to abnormal vasculature and altered stroma composition in neoplastic tissues. Coupling of chemotherapeutic drugs with tumor vasculature-homing peptides or administration of drugs in combination with biological agents that affect the integrity of the endothelial lining of tumor vasculature is an appealing strategy to improve drug delivery to tumor cells. Promising approaches to achieve this goal are based on the use of Asn-Gly-Arg (NGR)-containing peptides as ligands for drug delivery and of NGR-TNF, a peptide-tumor necrosis factor-α fusion protein that selectively alters drug penetration barriers and that is currently tested in a randomized Phase III trial in patients with malignant pleural mesothelioma.
化疗药物向肿瘤的递送和渗透受到多种因素的限制,这些因素与肿瘤组织中异常的血管生成和基质组成改变有关。将化疗药物与肿瘤血管靶向肽偶联,或联合应用可影响肿瘤血管内皮完整性的生物制剂,是改善药物向肿瘤细胞递送的一种有吸引力的策略。实现这一目标的有前途的方法是基于使用含有天冬酰胺-甘氨酸-精氨酸(NGR)的肽作为药物递送的配体,以及 NGR-TNF,一种肽-肿瘤坏死因子-α融合蛋白,它选择性地改变药物渗透屏障,目前正在恶性胸膜间皮瘤患者的随机 III 期试验中进行测试。